Oncoinfluencers to Follow on Social Media: Dr. Shikha Jain – OncoDaily
Oncoinfluencers to Follow on Social Media: Dr. Shikha Jain / cancer, health care, LinkedIn, OncoDaily, OncoInfluencers, Oncoinfluencers to Follow on Social
Related Articles
Desmoplastic Melanoma: 5-Minute Pathology Pearls
A complete organized library of all my videos, digital slides, pics, & sample pathology reports is available here: https://kikoxp.com/posts/5084 (dermpath) &…
Fauxcoll gradient
Fauxcoll gradient, Blood, Volume 115, Issue 13, 1 April 2010, Pages 2567, https://doi.org/10.1182/blood-2010-03-272575
Rare germline structural variants increase risk for pediatric solid tumors
Pediatric solid tumors are a leading cause of childhood disease mortality. In this work, we examined germline structural variants (SVs) as risk factors for pediatric…
Cleveland Clinic’s Dr. Chirag Shah joins Allegheny Health Network
He’ll be chief of radiation oncology.
Here’s what Rhode Island’s movers and shakers are watching for this year – The Boston Globe
Of course, they made a few predictions, too.
‘Very new’: Doctors are unionizing, from Mass General Brigham to Beth Israel. Here’s why. – The Boston Globe
Physicians at Mass General Brigham, Beth Israel, and Cambridge Health Alliance are driven by a conviction that their employers are putting business considerations over medical…
microsoft/BiomedCLIP-PubMedBERT_256-vit_base_patch16_224 · Hugging Face
We’re on a journey to advance and democratize artificial intelligence through open source and open science.
Advancing Drug Development in Myelodysplastic Syndromes
Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of all
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
Current evaluation of treatment response in solid tumors depends on dynamic changes in tumor diameters as measured by imaging. However, these changes can only be…
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
Nature Medicine – Results from this single-arm cohort of the BFAST trial showed that the clinical efficacy of entrectinib in patients with ROS1-positive NSCLC, selected…